Comparing VMAT2 Inhibitors and Formulations

Panelists discuss how the availability of both immediate- and extended-release formulations of deutetrabenazine and valbenazine offers flexibility in treatment. They note that extended-release options may enhance adherence by simplifying dosing schedules and reducing pill burden.

Panelists discuss how dosing regimens and pharmacokinetic profiles can affect patient experience, with some patients preferring once-daily dosing for convenience, while others benefit from split dosing to minimize adverse effects. Pharmacists are critical in explaining these differences and ensuring patients understand proper administration.

Panelists discuss how individualized selection between formulations should account for adherence patterns, adverse effect profiles, and patient lifestyle. A pharmacist’s guidance can improve both satisfaction and consistency with therapy, leading to sustained symptom control.